Under construction – not a live service
Sign in
Taking people in United StatesPhase 3

Daily ASC30 pill for adults with obesity or overweight and type 2 diabetes

Tests a daily ASC30 pill in adults with obesity and type 2 diabetes.

Plain-language title generated from the registry record
Registry title: A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Key facts

Where
Austin, Banning, Baton Rouge, Birmingham, Bluffton, Boca Raton, Boise, Bowie, Brownsville, Canton, Charlotte, Chula Vista, Cincinnati, Clemson, Cleveland, Columbia, Columbus, Covina, Dayton, Daytona Beach, Decatur, DeSoto, Durham, East Northport, East Syracuse, Eugene, Evansville, Frisco, Gaffney, Gardena, Greenville, Gulfport, Hampton, Houston, Huntsville, Indianapolis, Jackson, Jacksonville, Jersey City, Kansas City, La Mesa, Las Vegas, Leesburg, Little Rock, Los Angeles, Mankato, Melbourne, Memphis, Mesquite, Metairie, Morehead City, New Windsor, Oklahoma City, Olive Branch, Peoria, Philadelphia, Phoenix, Pittsburgh, Raleigh, Rockville, Sacramento, Salt Lake City, San Antonio, Schaumburg, Seattle, South Miami, Southfield, St Louis, Sugar Land, Tampa, Tarzana, The Villages, Tomball, Tucson, Tustin, Union City, Valparaiso, Washington D.C., Waxahachie, Weslaco, Wichita Falls, and Winter Park, United StatesSee the 82 sites
Phase
Phase 3

Where in United States

  • AustinAustin, United StatesTaking people
  • BanningBanning, United StatesNot yet recruiting
  • Baton RougeBaton Rouge, United StatesNot yet recruiting
  • BirminghamBirmingham, United StatesNot yet recruiting
  • BlufftonBluffton, United StatesNot yet recruiting
  • Boca RatonBoca Raton, United StatesNot yet recruiting
  • BoiseBoise, United StatesNot yet recruiting
  • BowieBowie, United StatesNot yet recruiting
  • BrownsvilleBrownsville, United StatesNot yet recruiting
  • CantonCanton, United StatesNot yet recruiting
  • CharlotteCharlotte, United StatesNot yet recruiting
  • Chula VistaChula Vista, United StatesNot yet recruiting
  • CincinnatiCincinnati, United StatesNot yet recruiting
  • ClemsonClemson, United StatesNot yet recruiting
  • ClevelandCleveland, United StatesNot yet recruiting
  • ColumbiaColumbia, United StatesNot yet recruiting
  • ColumbusColumbus, United StatesNot yet recruiting
  • CovinaCovina, United StatesNot yet recruiting
  • DaytonDayton, United StatesNot yet recruiting
  • Daytona BeachDaytona Beach, United StatesNot yet recruiting
  • DecaturDecatur, United StatesNot yet recruiting
  • DeSotoDeSoto, United StatesNot yet recruiting
  • DurhamDurham, United StatesNot yet recruiting
  • East NorthportEast Northport, United StatesNot yet recruiting
  • East SyracuseEast Syracuse, United StatesNot yet recruiting
  • EugeneEugene, United StatesNot yet recruiting
  • EvansvilleEvansville, United StatesTaking people
  • FriscoFrisco, United StatesNot yet recruiting
  • GaffneyGaffney, United StatesNot yet recruiting
  • GardenaGardena, United StatesNot yet recruiting
  • GreenvilleGreenville, United StatesNot yet recruiting
  • GulfportGulfport, United StatesNot yet recruiting
  • HamptonHampton, United StatesNot yet recruiting
  • HoustonHouston, United StatesNot yet recruiting
  • HuntsvilleHuntsville, United StatesNot yet recruiting
  • IndianapolisIndianapolis, United StatesNot yet recruiting
  • JacksonJackson, United StatesNot yet recruiting
  • JacksonvilleJacksonville, United StatesNot yet recruiting
  • Jersey CityJersey City, United StatesNot yet recruiting
  • Kansas CityKansas City, United StatesNot yet recruiting
  • La MesaLa Mesa, United StatesNot yet recruiting
  • Las VegasLas Vegas, United StatesNot yet recruiting
  • LeesburgLeesburg, United StatesNot yet recruiting
  • Little RockLittle Rock, United StatesNot yet recruiting
  • Los AngelesLos Angeles, United StatesNot yet recruiting
  • MankatoMankato, United StatesNot yet recruiting
  • MelbourneMelbourne, United StatesTaking people
  • MemphisMemphis, United StatesNot yet recruiting
  • MesquiteMesquite, United StatesNot yet recruiting
  • MetairieMetairie, United StatesNot yet recruiting
  • Morehead CityMorehead City, United StatesNot yet recruiting
  • New WindsorNew Windsor, United StatesNot yet recruiting
  • Oklahoma CityOklahoma City, United StatesNot yet recruiting
  • Olive BranchOlive Branch, United StatesNot yet recruiting
  • PeoriaPeoria, United StatesNot yet recruiting
  • PhiladelphiaPhiladelphia, United StatesNot yet recruiting
  • PhoenixPhoenix, United StatesTaking people
  • PittsburghPittsburgh, United StatesNot yet recruiting
  • RaleighRaleigh, United StatesNot yet recruiting
  • RockvilleRockville, United StatesNot yet recruiting
  • SacramentoSacramento, United StatesNot yet recruiting
  • Salt Lake CitySalt Lake City, United StatesNot yet recruiting
  • San AntonioSan Antonio, United StatesTaking people
  • SchaumburgSchaumburg, United StatesNot yet recruiting
  • SeattleSeattle, United StatesNot yet recruiting
  • South MiamiSouth Miami, United StatesNot yet recruiting
  • SouthfieldSouthfield, United StatesNot yet recruiting
  • St LouisSt Louis, United StatesNot yet recruiting
  • Sugar LandSugar Land, United StatesNot yet recruiting
  • TampaTampa, United StatesNot yet recruiting
  • TarzanaTarzana, United StatesNot yet recruiting
  • The VillagesThe Villages, United StatesTaking people
  • TomballTomball, United StatesNot yet recruiting
  • TucsonTucson, United StatesNot yet recruiting
  • TustinTustin, United StatesNot yet recruiting
  • Union CityUnion City, United StatesNot yet recruiting
  • ValparaisoValparaiso, United StatesNot yet recruiting
  • Washington D.C.Washington D.C., United StatesNot yet recruiting
  • WaxahachieWaxahachie, United StatesNot yet recruiting
  • WeslacoWeslaco, United StatesNot yet recruiting
  • Wichita FallsWichita Falls, United StatesNot yet recruiting
  • Winter ParkWinter Park, United StatesNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Ascletis Pharma (China) Co., Limited
Trial code
NCT07743450
Record updated
16 September 2026
Original description
Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight and T2DM.Read full original descriptionShow less

A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Once-Daily Oral ASC30 in Adult Participants With Obesity or Overweight With Type 2 Diabetes Mellitus (AURORA-2)

Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight and T2DM.

Inclusion: Participant must be ≥18 years of age inclusive, or the legal age of consent in the jurisdiction in which the study is taking place at screening; Have a BMI ≥ 27 kg/m2 at screening; Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight; Have a diagnosis of T2D according to the WHO classification or other locally applicable standards, with HbA1c > 6.5% (48 mmol/mol) to ≤10.5% (91 mmol/mol) at screening.

Exclusion: Have a self-reported change in body weight >5 kg (11 pounds) within 3 months prior to screening; Have a history of acute or chronic pancreatitis any time prior to screening; Are currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study at the investigator's discretion; Have Type 1 Diabetes Mellitus (T1DM), history of ketoacidosis or hyperosmolar state/coma, or any other types of diabetes except T2DM; Have known allergies or intolerance to glucagon-like peptide-1 Receptor Agonists (GLP-1 RA); Participants with a personal or family (first-degree relative) history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia (MEN) syndrome type 2; Have an estimated glomerular filtration rate (eGFR) < 15 mL/min/1.73 m2, as determined by the laboratory at screening.

ClinicalTrials.gov NCT07743450